The Cancer Genome Atlas (TCGA): The Genomic Map That Changed Cancer Research (2026)

Research Guide • Cancer Genomics • Precision Oncology • Multi-Omics

The Cancer Genome Atlas (TCGA) was one of the most ambitious cancer genomics programs ever undertaken. A joint initiative of the U.S. National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI), TCGA systematically characterized the molecular features of thousands of human tumors across 33 cancer types.

The project did something that cancer research had rarely been able to do at this scale: it examined cancer simultaneously through multiple biological layers — including DNA alterations, gene expression, epigenetics, copy-number changes, microRNAs, proteins and clinical information.

Why TCGA matters: cancer is not simply a collection of diseases defined by where a tumor is located. TCGA demonstrated how tumors can also be understood through their molecular alterations, signaling pathways, immune environments, metabolic characteristics, cell-of-origin patterns and other biological features.

NCI reports that TCGA characterized more than 20,000 primary cancer and matched-normal samples spanning 33 cancer types, representing contributions from more than 11,000 patients. Over approximately 12 years, the program generated more than 2.5 petabytes of genomic, epigenomic, transcriptomic and proteomic data. The program has ended, but its data remain available through the NCI Genomic Data Commons (GDC). NCI: The Cancer Genome Atlas Program

In This Guide

1. What is TCGA?
2. Why was TCGA created?
3. How TCGA worked
4. The multi-omics architecture of TCGA
5. The 33 cancer types studied
6. Major discoveries and research themes
7. The Pan-Cancer Atlas
8. TCGA and precision oncology
9. TCGA, biomarkers and molecular classification
10. TCGA and the cancer immune system
11. TCGA and cancer metabolism
12. TCGA and treatment resistance
13. Can TCGA data predict an individual patient's treatment?
14. Important limitations of TCGA
15. How researchers use TCGA today
16. From TCGA to the next generation of cancer atlases
17. Frequently Asked Questions
18. References and primary resources

What Is The Cancer Genome Atlas?

The Cancer Genome Atlas, commonly abbreviated TCGA, was a large-scale cancer genomics initiative launched through collaboration between the National Cancer Institute and NHGRI.

The project's central objective was to create a comprehensive molecular map of cancer. Instead of investigating only one mutation, one gene or one cancer pathway at a time, TCGA researchers collected and integrated many forms of molecular information from tumor specimens.

TCGA began with a pilot phase involving three cancers:

• Glioblastoma
• Ovarian serous carcinoma
• Lung squamous cell carcinoma

The pilot demonstrated that large-scale, multidimensional molecular characterization was feasible. TCGA then expanded into a broad program covering dozens of cancer types.

The first major TCGA publication appeared in Nature in 2008 and reported comprehensive genomic characterization of glioblastoma, helping establish the model of combining multiple genomic measurements to understand cancer biology.

Nature: Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Source: Nature 2013

TCGA changed the question from "Which mutation does this cancer have?" to a broader question: "What molecular system is operating inside this tumor?"

Why Was TCGA Created?

Cancer is caused by accumulated biological changes, but those changes are not identical from one tumor to another. Two tumors arising in the same organ can have different driver alterations, different gene-expression programs, different immune environments and different responses to therapy.

Before large-scale cancer genomics became practical, researchers often investigated cancer through individual pathways or relatively small groups of genes.

TCGA was designed to create a much larger evidence base.

Scale Thousands of tumors could be analyzed rather than relying only on small individual studies.

Depth Multiple molecular layers could be studied in the same disease program.

Comparison Researchers could compare molecular patterns across different cancer types.

This approach was especially important because cancer is heterogeneous. A tumor can contain multiple genetically and biologically distinct subpopulations of cells. A single molecular measurement may therefore provide only one part of the picture.

How Did TCGA Work?

TCGA was not simply a DNA sequencing project. It was an integrated pipeline involving biospecimen collection, molecular characterization, clinical annotation, computational analysis and data distribution.

For many projects, researchers sought primary untreated tumor specimens together with matched normal tissue or blood. NCI's selection criteria also addressed sample quality, consent and tumor cellularity. The program's requirements evolved as sequencing technologies improved.

Researchers then used multiple analytical platforms to characterize the samples.

Layer	What It Examines	Why It Matters
DNA mutations	Changes in DNA sequence	Can identify potentially important cancer-driving alterations
Copy-number alterations	DNA regions gained or lost	Can alter the dosage of cancer-related genes
Gene expression	RNA output from genes	Shows which biological programs are active or suppressed
DNA methylation	Epigenetic regulation of DNA	Provides information about gene regulation and cellular identity
microRNA	Small regulatory RNA molecules	Helps characterize post-transcriptional regulation
Protein expression	Abundance of selected proteins	Provides a closer connection to cellular signaling and function
Clinical data	Pathology and outcome-related information	Allows molecular features to be studied alongside clinical variables

NCI notes that the exact data types available varied according to cancer type, sample quality, quantity and technology available at the time. Some raw and potentially identifying data are controlled-access, while many processed and derived datasets are openly available through the GDC.

NCI: TCGA Data Types · NCI: TCGA Molecular Characterization Platforms

The Multi-Omics Architecture of TCGA

One of TCGA's most important contributions was the idea that cancer should be studied across several biological "omics" layers rather than through isolated measurements.

Consider a simplified sequence:

DNA mutation → altered signaling → altered transcription → altered protein activity → altered cell behavior → interaction with the tumor microenvironment → clinical phenotype

That chain is not deterministic in every tumor. Biology is more complicated. But it illustrates why a mutation alone may not fully explain what a cancer cell is actually doing.

For example, a tumor may carry a mutation in a signaling gene but have compensatory pathways activated elsewhere. Another tumor may have a similar mutation but a completely different immune microenvironment or epigenetic state.

TCGA made it possible to investigate those interactions at population scale.

A useful mental model: Think of TCGA as a layered cancer map.

Genome = the underlying code

Epigenome = regulatory controls

Transcriptome = which genes are being expressed

Proteome = proteins and signaling machinery

Microenvironment = surrounding cells and immune context

Clinical phenotype = how the disease presents and behaves

Which Cancers Were Studied by TCGA?

TCGA ultimately covered 33 cancer types or disease groupings. The official NCI list includes both common malignancies and rarer cancers.

Cancer / TCGA Project	Common Abbreviation	Cancer Family
Acute Myeloid Leukemia	LAML	Blood cancer
Adrenocortical Carcinoma	ACC	Endocrine/adrenal
Bladder Urothelial Carcinoma	BLCA	Genitourinary
Breast Invasive Carcinoma	BRCA	Breast
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	CESC	Gynecologic
Cholangiocarcinoma	CHOL	Biliary tract
Colon Adenocarcinoma	COAD	Gastrointestinal
Rectum Adenocarcinoma	READ	Gastrointestinal
Esophageal Carcinoma	ESCA	Gastrointestinal
Gastric Adenocarcinoma	STAD	Gastrointestinal
Glioblastoma	GBM	Brain/CNS
Lower Grade Glioma	LGG	Brain/CNS
Head and Neck Squamous Cell Carcinoma	HNSC	Head and neck
Hepatocellular Carcinoma	LIHC	Liver
Kidney Chromophobe	KICH	Kidney
Kidney Renal Clear Cell Carcinoma	KIRC	Kidney
Kidney Renal Papillary Cell Carcinoma	KIRP	Kidney
Lung Adenocarcinoma	LUAD	Lung
Lung Squamous Cell Carcinoma	LUSC	Lung
Mesothelioma	MESO	Thoracic
Ovarian Serous Carcinoma	OV	Gynecologic
Pancreatic Adenocarcinoma	PAAD	Pancreas
Paraganglioma and Pheochromocytoma	PCPG	Neuroendocrine/endocrine
Prostate Adenocarcinoma	PRAD	Genitourinary
Sarcoma	SARC	Connective tissue
Skin Cutaneous Melanoma	SKCM	Skin
Testicular Germ Cell Tumors	TGCT	Genitourinary
Thymoma	THYM	Thoracic
Thyroid Carcinoma	THCA	Endocrine
Uterine Corpus Endometrial Carcinoma	UCEC	Gynecologic
Uterine Carcinosarcoma	UCS	Gynecologic
Uveal Melanoma	UVM	Eye

TCGA project terminology and groupings have evolved in different datasets and publications. The NCI's official study list should be treated as the definitive reference when exact project definitions matter.

NCI: TCGA Cancers Selected for Study

What Did TCGA Discover?

TCGA generated thousands of findings and became the foundation for an enormous amount of subsequent cancer research. It is therefore more accurate to describe its contribution as a research platform and reference atlas than as a single discovery.

1. Cancer genomes contain recurrent driver alterations

Large-scale datasets allowed researchers to distinguish more systematically between random mutations and recurrent alterations that may contribute to cancer development.

In a major Pan-Cancer analysis involving 9,423 tumor exomes and 26 computational approaches, researchers identified 299 cancer driver genes and thousands of candidate driver mutations supported by multiple lines of evidence.

GDC: Comprehensive Characterization of Cancer Driver Genes and Mutations

2. Cancer types can share molecular pathways

Traditional oncology often starts with anatomy: breast cancer, lung cancer, colon cancer, pancreatic cancer and so forth.

TCGA enabled researchers to look horizontally across those boundaries.

Researchers could ask whether cancers from different organs shared alterations in the same signaling pathways, DNA-repair systems, immune programs or transcriptional states.

This does not mean cancers from different organs are interchangeable. Tissue of origin remains extremely important. Rather, it suggests that certain molecular mechanisms can recur across anatomical cancer categories.

3. Tissue of origin remains a powerful biological signal

The Pan-Cancer Atlas found that molecular classification across approximately 10,000 tumors was strongly influenced by tissue type, histology and cell of origin.

This finding is important because it provides a useful counterweight to the idea that cancer should be classified solely according to mutations.

A molecular alteration exists within a biological context. The same pathway may behave differently depending on the lineage and cellular environment in which it occurs.

GDC: Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors

4. Cancer is a systems biology problem

Perhaps the most important conceptual contribution of TCGA was demonstrating the value of integration.

DNA alterations alone do not capture the entire state of a tumor. Gene expression alone does not capture it either. Protein activity, epigenetic regulation, immune infiltration, aneuploidy, tumor purity and clinical context can all modify the biological meaning of a molecular finding.

This systems-level view is one reason TCGA remains so useful years after the original program ended.

The Pan-Cancer Atlas

Near the end of the TCGA program, researchers undertook a major cross-cancer analysis known as the Pan-Cancer Atlas.

The goal was to move beyond separate cancer-type projects and search for overarching biological themes across the 33 TCGA tumor types.

The PanCanAtlas examined subjects including:

• Cell of origin and molecular classification
• Oncogenic signaling pathways
• Cancer driver genes and mutations
• Tumor immune landscapes
• Metabolism
• Stemness and dedifferentiation
• DNA repair and genomic instability
• Epigenetic regulation
• Enhancers and gene regulation
• Clinical outcomes and survival analytics

The result was not one giant "cancer gene list." It was a set of integrated analyses that looked for recurring biological patterns across cancer types.

NCI GDC: TCGA PanCanAtlas Publications

Why Pan-Cancer analysis matters: A mechanism discovered in one cancer may become a hypothesis for another cancer when molecular similarities exist. But similarity is a starting point for research, not proof that the same treatment will work in both diseases.

TCGA and Precision Oncology

Precision oncology attempts to match cancer biology with diagnostic, prognostic or therapeutic strategies.

TCGA helped create the underlying knowledge base for this approach by cataloging alterations across large numbers of tumors.

A simplified precision-oncology chain looks like this:

Step	Question	Example Biological Layer
1. Diagnose	What type of cancer is present?	Histology and pathology
2. Characterize	What molecular abnormalities exist?	DNA sequencing, copy number
3. Interpret	Which pathways may be biologically important?	RNA, protein, pathway analysis
4. Stratify	Does the tumor fit a recognized molecular subgroup?	Molecular subtype
5. Match	Are there clinically validated treatments associated with the finding?	Biomarker-treatment evidence
6. Monitor	Has tumor biology changed?	Repeat profiling, when clinically appropriate

TCGA primarily provides the research infrastructure and biological reference information. A clinical decision requires a separate layer of evidence: validated diagnostic assays, clinical trials, regulatory approvals, treatment guidelines, patient-specific factors and the actual tumor profile of the individual patient.

TCGA, Biomarkers and Molecular Classification

A biomarker is a measurable biological characteristic that can provide information about disease biology, prognosis, treatment response or another clinically relevant feature.

TCGA helped researchers examine many biomarker concepts simultaneously.

Examples include:

Mutation biomarkers Examples include alterations affecting TP53, KRAS, BRAF and other cancer-related genes.

Genomic instability Copy-number alterations, aneuploidy and DNA-repair abnormalities can reveal distinct tumor states.

Immune biomarkers Immune-cell signatures, inflammatory programs and other features can help describe the tumor immune environment.

Importantly, a mutation is not automatically a clinically useful biomarker.

A molecular alteration can be:

• Biologically interesting but not clinically actionable
• Potentially actionable but lacking sufficient clinical evidence
• Clinically validated for a particular disease and treatment context

This distinction is fundamental to responsible interpretation of cancer genomics.

TCGA finding ≠ treatment recommendation. TCGA can reveal a molecular relationship or generate a therapeutic hypothesis. Clinical practice requires evidence beyond the existence of a genomic association.

TCGA and the Cancer Immune System

One particularly influential PanCanAtlas analysis examined the immune landscape of cancer across more than 10,000 tumors representing 33 cancer types.

Researchers described six broad immune subtypes based on patterns involving immune-cell signatures, inflammatory signaling, lymphocyte levels, TGF-β activity, interferon signaling, proliferation and other features.

The six reported immune subtypes were:

1. Wound Healing
2. IFN-γ Dominant
3. Inflammatory
4. Lymphocyte Depleted
5. Immunologically Quiet
6. TGF-β Dominant

This work reinforced an important principle of immuno-oncology: the presence of a cancer-associated mutation does not fully describe whether a tumor is immunologically active or suppressed.

The immune environment can influence how the tumor interacts with therapeutic strategies, including immunotherapies.

GDC: The Immune Landscape of Cancer

TCGA and Cancer Metabolism

Cancer metabolism became another major area of analysis using TCGA data.

Cancer cells frequently alter how they obtain, process and use nutrients and energy. These changes can involve glucose metabolism, lipid metabolism, amino-acid metabolism, mitochondrial pathways and biosynthetic processes.

TCGA enabled investigators to examine metabolic gene-expression programs across cancers rather than studying metabolism only within one tumor type.

One PanCanAtlas publication specifically investigated metabolic expression subtypes across human cancers.

GDC: PanCanAtlas publications, including metabolic expression subtype analysis

This is particularly relevant to the growing field of immunometabolism and metabolic oncology, where researchers investigate relationships among:

• tumor nutrient utilization
• hypoxia
• mitochondrial function
• immune-cell metabolism
• redox biology
• lactate and acidic tumor environments
• metabolic adaptation during treatment

Important: TCGA metabolic associations should be interpreted as molecular and observational evidence unless supported by functional experiments or clinical trials. A gene-expression signature does not automatically establish that changing a patient's diet or targeting a metabolic pathway will improve survival.

TCGA and Cancer Treatment Resistance

One of the most important reasons to study cancer genomics is that tumors evolve.

A tumor may initially respond to treatment and later develop or select for resistant populations. Resistance can arise through several mechanisms:

Resistance Mechanism	Biological Concept	TCGA-Relevant Data Layer
Target alteration	The treatment target changes or becomes activated differently	DNA sequencing
Pathway bypass	Another signaling pathway compensates for the inhibited pathway	RNA/protein/pathway analysis
Gene amplification or deletion	Changes in gene dosage modify tumor behavior	Copy-number analysis
Epigenetic adaptation	Gene regulation changes without requiring a new DNA mutation	Methylation/expression data
Immune escape	The tumor alters interactions with immune cells	Immune signatures/expression
Clonal selection	Pre-existing resistant populations expand under treatment pressure	Genomic heterogeneity

TCGA is especially valuable for studying the baseline architecture of cancer. However, it is not the same thing as longitudinal sequencing of an individual patient's tumor before, during and after treatment.

That distinction matters enormously when studying resistance.

A useful research framework is:

Driver → Pathway → Phenotype → Treatment Pressure → Escape Mechanism → Resistant State → Next Treatment Hypothesis

Can TCGA Data Predict an Individual Patient's Treatment?

Not by itself.

TCGA is a population-level research dataset. It can reveal associations between molecular characteristics and clinical outcomes, but an individual patient may differ substantially from the tumors represented in the dataset.

There are several reasons.

1. The sample may not represent the current tumor

Cancer evolves. A biopsy obtained at diagnosis may not fully represent a metastatic lesion years later.

2. Tumors are heterogeneous

Different regions of the same tumor can contain different clones and different microenvironments.

3. TCGA is not a randomized treatment trial

Associations in TCGA cannot automatically establish that a molecular alteration causes a particular clinical outcome or that targeting it will improve that outcome.

4. Treatment standards have changed

TCGA accumulated samples over many years. Modern oncology includes therapies and biomarker-defined strategies that were unavailable or less developed during much of the original program.

5. Clinical data have limitations

The TCGA Pan-Cancer Clinical Data Resource was created partly because researchers had to address inconsistencies and statistical challenges in integrating clinical outcome information across cancer types.

GDC: An Integrated TCGA Pan-Cancer Clinical Data Resource

The right use of TCGA: use it to understand cancer biology, generate hypotheses, identify molecular patterns, compare tumor groups and support research. Combine those findings with validated clinical evidence before applying them to patient care.

Important Limitations of TCGA

TCGA is extraordinarily valuable, but it should not be treated as a perfect representation of every cancer patient.

Limitation	Why It Matters
Selection bias	Available tissue, consent, sample quality and study criteria influence which tumors enter the dataset.
Tumor purity	Bulk tumor samples contain mixtures of malignant and non-malignant cells.
Spatial heterogeneity	A single tissue sample may not capture every region of a tumor.
Temporal heterogeneity	A baseline tumor can differ from a recurrent or treatment-resistant tumor.
Platform differences	Technology changed substantially during the 12-year project.
Unequal sample sizes	Some cancers are represented by much larger cohorts than rare tumor types.
Association versus causation	Correlations from observational datasets require additional biological and clinical validation.
Historical treatment context	Older clinical data may not reflect current treatment standards.

These limitations do not diminish TCGA's value. Instead, they define how the data should be interpreted.

How Researchers Use TCGA Today

Although the original TCGA program has ended, the dataset remains an active research resource.

NCI states that TCGA data are available through the Genomic Data Commons (GDC), which provides access, search, analysis and visualization tools.

Access TCGA through the NCI Genomic Data Commons

Researchers commonly use TCGA for:

• gene-expression analysis
• mutation and driver-gene research
• survival and prognostic analyses
• molecular subtype discovery
• immune-infiltration studies
• pathway analysis
• metabolic-expression studies
• drug-target research
• biomarker discovery
• machine-learning model development
• cross-cancer comparisons
• validation of findings from independent experiments

TCGA and cBioPortal

Researchers and advanced users can also explore TCGA data through tools such as cBioPortal for Cancer Genomics.

cBioPortal can make complex cancer genomics more accessible by allowing users to investigate mutations, copy-number changes, clinical features and other molecular characteristics in an interactive environment.

TCGA and the GDC

The GDC is especially important because it is now the main NCI infrastructure through which TCGA data can be accessed.

NCI's GDC describes TCGA as a landmark program that molecularly characterized more than 20,000 primary cancer and matched normal samples across 33 cancer types.

GDC: TCGA Resources

From TCGA to the Next Generation of Cancer Atlases

TCGA was designed around the technologies available during its era. Cancer genomics has continued to evolve rapidly.

Modern cancer research can add technologies such as:

• single-cell sequencing
• single-cell RNA sequencing
• spatial transcriptomics
• long-read sequencing
• more comprehensive whole-genome sequencing
• advanced proteomics
• immune-repertoire profiling
• digital pathology
• functional screening
• patient-derived models
• longitudinal liquid biopsy monitoring

This means the modern cancer atlas is becoming less like a static library and more like a dynamic map of tumor evolution.

TCGA mapped the cancer genome.
The next generation of cancer research increasingly asks how that genome interacts with the transcriptome, proteome, immune system, metabolism, microenvironment and treatment pressure over time.

TCGA in the Era of the Cancer Knowledge Graph

For cancer information systems, TCGA is particularly important because it provides a foundation for linking multiple dimensions of cancer biology.

A modern cancer knowledge graph can connect:

Cancer Type → Histology → Biomarker → Mutation → Pathway → Tumor Microenvironment → Treatment → Response → Resistance Mechanism → Next Treatment

For example, a cancer research system might start with a specific tumor and ask:

Question	Relevant Evidence Layer
What cancer is this?	Pathology and histology
What genes are altered?	Somatic and germline genomics
Which pathways are activated?	Transcriptomics, proteomics and pathway analysis
Is the tumor immunologically active?	Immune signatures and tumor microenvironment
Are DNA-repair mechanisms impaired?	Genomic and functional biomarkers
Does the tumor resemble a known molecular subtype?	Integrated molecular classification
What treatments are clinically supported?	Guidelines, trials and treatment evidence
Why might resistance occur?	Longitudinal genomics plus functional and clinical evidence

This is where TCGA becomes more than a historical project. It is one of the foundational datasets behind the transition from anatomy-based cancer classification toward increasingly integrated molecular oncology.

What TCGA Does — and Does Not — Tell Us

TCGA Can Help With	TCGA Cannot Establish Alone
Identifying recurrent molecular alterations	That a mutation will respond to a particular treatment in every patient
Comparing molecular patterns among cancers	That two cancers from different organs are clinically interchangeable
Studying gene-expression programs	That changing one gene or pathway will necessarily improve survival
Generating biomarker hypotheses	That every biomarker is clinically validated
Studying immune and metabolic patterns	That an immune or metabolic signature is itself a treatment
Supporting cancer research and computational models	A personalized treatment plan for an individual patient

Why the Cancer Genome Atlas Still Matters

The importance of TCGA is not simply the number of tumor samples it generated.

Its larger contribution was methodological.

TCGA helped establish the expectation that cancer should be studied using large datasets, standardized molecular characterization, integrated multi-omics analysis, computational biology and publicly accessible research resources.

It also demonstrated that common biological mechanisms can cross anatomical boundaries while tissue of origin remains critically important.

That combination is central to modern precision oncology.

The central lesson of TCGA: cancer is not one disease, and it is not adequately described by one gene, one pathway or one biomarker. Cancer is a dynamic biological system operating across multiple molecular and cellular layers.

For researchers, clinicians, data scientists and medically sophisticated readers, TCGA remains a foundational reference point for understanding those layers.

Frequently Asked Questions About TCGA

What does TCGA stand for?

TCGA stands for The Cancer Genome Atlas, a joint cancer genomics initiative of the U.S. National Cancer Institute and National Human Genome Research Institute.

How many cancer types were studied by TCGA?

TCGA ultimately characterized tumors spanning 33 cancer types, including common and rare cancers.

How many patients were included in TCGA?

NCI describes the program as involving contributions from more than 11,000 patients and more than 20,000 primary cancer and matched-normal samples.

Is TCGA still collecting samples?

No. The TCGA characterization program has been completed and is no longer accepting samples for characterization. Its data remain available through the NCI Genomic Data Commons.

Where can I access TCGA data?

TCGA data can be accessed through the NCI Genomic Data Commons Data Portal. Some data are open access while certain raw or sensitive datasets require controlled access.

What types of data does TCGA contain?

TCGA includes multiple molecular and clinical data types, including DNA alterations, copy-number data, RNA expression, microRNA, DNA methylation, protein-expression measurements and clinical information, although the available data varied by cancer type and sample.

Is TCGA useful for precision oncology?

Yes. TCGA is an important research resource for identifying molecular alterations, studying pathways and biomarkers, comparing tumors and generating hypotheses relevant to precision oncology. However, TCGA alone does not establish an individualized treatment recommendation.

What is the Pan-Cancer Atlas?

The Pan-Cancer Atlas is a set of cross-cancer analyses built largely from TCGA data. It investigated broad themes including cell of origin, oncogenic pathways, cancer drivers, immune states, metabolism, stemness and clinical outcomes across cancer types.

Editorial Perspective

The Cancer Genome Atlas is best understood neither as an old database nor as a magic key to cancer treatment.

It is a reference map.

It provides the molecular landscape needed to ask better questions:

Which mutations matter? Which pathways are active? Which tumors share biological mechanisms? How does tissue of origin shape those mechanisms? What does the immune environment look like? What metabolic programs are active? Which features correlate with outcomes? And how might these findings connect to treatment and resistance?

The answers increasingly require integration across genomics, pathology, immunology, metabolism, proteomics and clinical medicine.

That is the enduring legacy of TCGA — not simply a list of cancer mutations, but a framework for understanding cancer as a complex and evolving system.

References and Primary Resources

1. National Cancer Institute. The Cancer Genome Atlas Program. https://www.cancer.gov/ccg/research/genome-sequencing/tcga
2. National Cancer Institute. TCGA Cancers Selected for Study. https://www.cancer.gov/ccg/research/genome-sequencing/tcga/studied-cancers
3. National Cancer Institute. TCGA Data Types. https://www.cancer.gov/ccg/research/genome-sequencing/tcga/using-tcga-data/types
4. National Cancer Institute. TCGA Molecular Characterization Platforms. https://www.cancer.gov/ccg/research/genome-sequencing/tcga/using-tcga-data/technology
5. NCI Genomic Data Commons. TCGA Resources. https://gdc.cancer.gov/about-data/gdc-data-processing/resources-tcga-users
6. NCI Genomic Data Commons. TCGA PanCanAtlas Publications. https://gdc.cancer.gov/about-data/publications/pancanatlas
7. TCGA Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. DOI: 10.1038/nature07385. Nature
8. Bailey P, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018;173:371–385.e18. DOI: 10.1016/j.cell.2018.02.060. GDC publication record
9. Thorsson V, et al. The Immune Landscape of Cancer. Immunity. 2018;48:812–830.e14. DOI: 10.1016/j.immuni.2018.03.023. GDC publication record
10. Hoadley KA, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 2018;173:291–304.e6. DOI: 10.1016/j.cell.2018.03.022. GDC publication record
11. NCI Genomic Data Commons. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High Quality Survival Outcome Analytics. Cell. 2018;173:400–416.e11. DOI: 10.1016/j.cell.2018.02.052. GDC publication record

Medical information disclaimer: This article is an educational overview of cancer genomics and research data. TCGA findings are not, by themselves, a diagnosis or individualized treatment recommendation. Cancer treatment decisions should be based on the patient's cancer type, stage, pathology, validated biomarker testing, current clinical evidence and discussion with qualified oncology professionals.